• April 30, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., today reported its financial results for the first quarter of 2013. The company reported revenues of $1.09 billion for the first quarter, an increase of 4% from the first quarter of 2012. Revenues reflected an operational2 increase of 5%, with foreign currency having a negative impact of 1%. Net income for the first quarter of 2013 was $140 million, or $0.28 permore...
  • March 28, 2013
    MADISON, N.J.--(BUSINESS WIRE)--The Board of Directors of ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a second-quarter dividend payable to holders of the company’s Class A common stock and Class B common stock of $0.065 per share. The dividend is to be paid on June 6, 2013, to holders of record on May 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting itsmore...
  • March 26, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, April 30, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call.Investors and the public may access the live webcast by visiting the Zoetismore...
  • February 6, 2013
    MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing. Zoetis did not receive any of the proceedsmore...
  • August 13, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal healthmore...
  • June 7, 2012
    NEW YORK--Pfizer Inc. (NYSE: PFE) today announced the next steps in the strategic alternatives review process for the company's Animal Health business. Preparations are underway to file a registration statement in the U.S. for a potential initial public offering (IPO) of a minority ownership stake in the new company. Pfizer expects to provide details regarding the proposed transaction as part of its 2012 second quarter earnings announcement.more...
  • April 13, 2012
    Four European academic research groups, together with Pfizer Animal Health, have forged a new research consortium to combat uterine disease - a problem that costs the EU dairy industry about €1.4billion annually.Called the IPUD research project (Integrated systems approach for Preventing Uterine Disease in dairy cattle), the collaboration involves academic research groups at Swansea University, the University of Glasgow in the UK, the University of Veterinary Medicine of Hannover in Germanymore...
  • November 8, 2011
    Pfizer Animal Health affirmed its commitment to innovation in equine health with the opening today of the Pfizer Animal Health Equine Research Center in Richland, Mich.  The center, the culmination of a $7 million investment, expands Pfizer Animal Health’s global research and development network headquarters in Kalamazoo, Mich., and will serve as the worldwide hub for research and development of equine vaccines and novel therapeutics. “The dedication of the Equine Research Center buildsmore...
  • November 4, 2011
    Pfizer Animal Health, a business unit of Pfizer (NYSE: PFE), and Jilin Guoyuan Animal Health Co., Ltd., announced today the establishment of the joint venture Jilin Pfizer Guoyuan Animal Health Co., Ltd. The joint venture, which has been granted a license by local Chinese government authorities, formalizes the strategic agreement signed on September 8 to develop, manufacture, and distribute animal vaccines in China. Terms of the agreement were not disclosed.The new company will focus initiallymore...
  • October 18, 2011
    Pfizer Animal Health and The Resource Foundation announced today the expansion of a comprehensive education and training program to increase the capacity, productivity and quality of life of rural farmers in eight Latin American countries.  Plans call for tailoring the program to the needs of rural communities in India.  The agreement was guided by results of a decade-long collaboration also announced today. Pfizer Animal Health and the Pfizer Foundation have committed $460,000 inmore...